CRISPR Therapeutics AG
CRSP
$48.41
-$2.04-4.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.61% | -250.07% | -23.85% | -64.98% | -16.64% |
| Total Depreciation and Amortization | -8.80% | 16.91% | -6.46% | -4.05% | -2.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.84% | 43.73% | -55.86% | 587.70% | 103.86% |
| Change in Net Operating Assets | -128.09% | 192.95% | 127.03% | -257.41% | -73.94% |
| Cash from Operations | -101.86% | -84.99% | 20.84% | -19.14% | -149.15% |
| Capital Expenditure | -144.66% | -103.54% | 66.21% | 83.45% | 71.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,998.52% | -64.45% | 26.17% | 155.54% | 79.86% |
| Cash from Investing | -1,979.19% | -64.85% | 26.22% | 155.14% | 79.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -41.84% | 589.82% | 2,978.49% | -- | -96.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5,490.37% | 589.82% | 2,978.49% | 584.55% | -96.54% |
| Foreign Exchange rate Adjustments | -178.05% | 101.15% | -136.00% | 3,900.00% | 472.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 214.53% | -15.88% | 135.89% | 81.36% | -119.84% |